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clinical trials are looking at the effect of Fluoxetine when 
given 2-15 days following stroke onset, including the AFFINITY 
(Assessment oF FluoxetINe In sTroke recoverY) trial in Australia, 
the FOCUS (Fluoxetine Or Control Under Supervision) trial in 
the United Kingdom, and the EFFECTS (Efficacy oF Fluoxetine–a 
randomizEd Controlled Trial in Stroke) trial in Sweden [4]. Since 
the majority of patients coming into the hospital are already 
on statins due to dyslipidemia, the purpose of this study was to 
examine whether administering fluoxetine at an earlier time-
Introduction
Only a small percentage of acute ischemic stroke patients 
reach the hospital in time to be considered for treatment with 
recombinant tissue plasminogen activator (rtPA),which can 
minimize permanent brain damage and reduce the risk of long-
term disability [1]. Fluoxetine, a selective serotonin reuptake 
inhibitor (SSRI), has been recently shown to enhance motor 
functional recovery after ischemic stroke [2,3]. Several ongoing 
Appropriate Timing of Fluoxetine and Statin 
Delivery Reduces the Risk of Secondary 
Bleeding in Ischemic Stroke Rats
Abstract
Background: Ongoing clinical trials are testing the effect of fluoxetine delivered 
post-stroke where a majority of patients are taking statins. This study determined 
the influence of the timing of administration of fluoxetine and statin on the final 
infarct volume and the risk of secondary bleeding in an animal model of ischemic 
stroke.
Methods and findings: Ischemic strokes were induced by endothelin-1 injection 
into two cortical sites of 10-12 month old female rats, targeting the forelimb motor 
cortex. Combined medications (5 mg/kg fluoxetine and 1 mg/kg simvastatin) 
were orally administered either beginning 6-12 hours or 20-26 hours after stroke 
induction and continued daily for 90 days. Infarct volumes were assessed at post-
stroke day 91 using Nissl stained coronal brain sections. 
Control animals typically had 5-13 mm3 infarct volumes following endothelin-1 
induced stroke. Animals that received fluoxetine and simvastatin (FS) beginning 20-
26 hours after stroke induction showed a strong trend of reduced infarct volume 
(3±0.3447 mm3 SEM, P=0.0563). Earlier drug delivery (6-12 hours after stroke) 
resulted in significantly larger infarct volumes (15.44.260 mm3 SEM, P=0.0157) 
when the drug groups were directly compared. Examination of the infarcts 
showed that earlier drug delivery induced secondary hemorrhagic infarcts, while 
later delivery did not (P=0.0427; Fisher’s exact test).
Conclusion: There is a danger of secondary bleeding if fluoxetine and simvastatin 
are combined within 6-12 hours of ischemic stroke induction in rats resulting in 
larger infarct volumes. Delaying fluoxetine and simvastatin delivery to 20-26 hours 
after stroke induction in rats, however, reduces infarct volume and significantly 
lowers the risk of secondary hemorrhagic infarcts.
Keywords: Ischemic Stroke, Secondary Hemorrhagic Stroke, Fluoxetine, 
Simvastatin, Infarct Volume
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point after stroke onset in combination with a statin could 
improve outcomes. In this study, we measured infarct volume 
differences when fluoxetine was administered either 6-12 hours 
or 20-26 hours after stroke induction in 10-12 month old rats.
Materials and Methods
Subjects
All animal work was approved by the Institutional Animal Care 
and Use Committee at Wright State University, and all procedures 
followed were in accordance with institutional guidelines. 
Animals used were 10-12 month old female Sprague-Dawley rats 
(generally 300-400 grams), obtained from Harlan Laboratories 
(Indianapolis, IN) and fed Harlan rat chow. The specific groups 
are indicated in Table 1.
Functional tests 
Montoya staircase: Rats were fasted overnight and then placed 
on a restricted diet consisting of 85% of their ad lib rat chow while 
they were trained to pick up sucrose pellets on the Montoya 
Staircase [5]. The Montoya Staircase consists of a raised platform 
with seven stairwells on each side containing sucrose pellets 
(three per stairwell) on each side of the platform, allowing left 
and right forelimb function to be assessed. Training occurred 
during the dark-phase and consisted of 15 minute trials inside 
the Montoya Staircase with sucrose pellets that have been 
painted with maple extract; the maple odor helps the rats locate 
the sucrose pellets on the stair wells. Training generally lasts 
anywhere from 10-14 days. At the end of the training period, the 
rat’s pre-stroke performance was determined by the best overall 
performance (total pellets taken) during the last three days of 
training. Animals must have learned to pick up at least 9 pellets 
with both their left and right forepaws or they were excluded 
from the Montoya Staircase analysis. The majority of animals 
learned to retrieve between 15-18 pellets with both paws. At 3-5 
days post-stroke the rats were tested on the Montoya Staircase 
again, and their best performance (total pellets taken) was used 
as a measure of their post-stroke baseline performance. To 
normalize their performance, we divided the number of pellets 
taken by each paw post-stroke by the number of pellets taken by 
each paw pre-stroke. Thus, when the quotient was 1, the animal 
had fully regained pre-stroke function in a particular limb and 
when the quotient was less than 1, the animal had a functional 
deficit in that limb. Animals that failed to reach training criteria 
on Montoya Staircases were tested on Forelimb Asymmetry.
Forelimb asymmetry: Animals were placed in a clear vertical 
cylinder and videotaped for 5 minutes. Rats would rear up and 
touch the walls of the cylinder with their right and left forepaws 
to explore their environment. Normally, pre-stroke, the majority 
of rats showed little preference for the right or left paw during 
this exploration behavior. However, when rats were again tested 
on post-stroke day 4, they showed a preference for touching the 
wall with their ipsilateral (right) paw, while they held their left 
paw back toward their body. In this analysis we looked at the 
percentage of touches to the wall by right or left paw post-stroke 
and divided that by their pre-stroke performance percentages. 
Again, when the quotient was 1, the animal had fully regained 
pre-stroke function and when the quotient was less than 1, 
the animal had a functional deficit in that limb. In this test in 
particular, the increased percentage of right paw use gave us 
values greater than 1.
Surgery for stroke induction
Anesthesia was induced with 5% isoflurane, and then the animals 
were maintained on 2-2.5% isoflurane using an anesthesia mask 
on the stereotactic apparatus (Stoelting Co., USA). The basic 
surgical procedures are as described in a previous study[6], 
with the following modifications: two holes were drilled in 
the skull, with positions relative to Bregma of (0.0 mm A.P., 
2.5 mm M.L.) and (1.5 mm A.P., and 2.5 mm M.L.). The needle 
containing endothelin-1 was inserted into both holes in the skull, 
then lowered to a depth of 2 mm. One and one-half microliters 
of endothelin-1 (600 pmol) was injected into each hole over a 
period of about 5 minutes. These positions were chosen to target 
the forelimb motor cortex in rats [7].
Treatment conditions
Two different time-points were chosen for initiating 5 mg/
kg fluoxetine and 1 mg/kg simvastatin after stroke induction: 
6-12 hours (12 animals per group) and 20-26 hours (8 animals 
per group). Animals were randomly assigned to either drug or 
control group after the surgery, but before the baseline stroke 
deficit was determined using either Montoya Staircase or 
Forelimb Asymmetry tests. After drug treatment was begun, it 
was continued daily for a period of 90 days, using voluntary oral 
administration of the drugs [8]. Briefly, this involves putting the 
drugs in a 4 gram ball of sugar cookie dough and allowing the 
animals to eat it. Control animals receive the 4 gram ball of sugar 
cookie dough with no drugs added.
Group Gender/ Strain Weight  at Stroke (mean±SD) Drugs (oral) Age at Stroke
6-12 hrs.  Control Female /Sprague Dawley 329 ± 21.4 gm None 10.5 months
6-12 hrs. FS Female/Sprague Dawley 332 ± 30.9 gm
1 mg/kg statin
5 mg/kg fluoxetine 10.5 months
20-26 hrs. Control Female/Sprague Dawley 316 ± 19.5 gm None 10.5 months
20-26 hrs. FS Female/Sprague Dawley 322 ± 27.6 gm
1 mg/kg statin
5 mg/kg fluoxetine 10.5 months
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drugs chosen would work to increase neurogenesis [11-14]. Three 
days prior to the stroke, the rats were introduced to the vehicle 
that would contain their drugs or serve as a vehicle control (4 
grams of sugar cookie dough, Pillsbury®) to allow them to get 
over their avoidance of novel foods; their pre-stroke baseline 
performance in Montoya Staircase and Forelimb Asymmetry was 
assessed. To be included in the functional analysis, rats had to pick 
up at least 9 sucrose pellets with each forepaw in the Montoya 
Staircase test and show at least a 20% functional deficit. The rats 
displayed similar post-stroke function in the contralateral paw 
in each of the time groups: in the 6-12 hours treatment groups, 
the mean contralateral function was 0.30±0.32 (mean±SD) in 
the FS group and 0.33±0.28 in the control group. In the 20-26 
hours treatment groups, the post-stroke mean contralateral 
function was 0.525±0.31 for the FS group and 0.37±0.27 for the 
control group. There was no statistical difference in the functional 
deficits on the contralateral forepaw between the drug and 
control groups. In some cases, we would see a bilateral deficit, 
and when those infarcts were examined, the infarcts generally 
involved a portion of the corpus callosum. Infarcts were induced 
with endothelin-1 injections at the forelimb motor cortex, and 
drug treatment with 5 mg/kg fluoxetine and 1 mg/kg simvastatin 
was begun either 6-12 hours OR 20-26 hours after stroke 
induction. These drug dosages correlate to approximately a 40 
mg fluoxetine dose and a 10 mg dose of simvastatin in humans 
[15]. This amount of fluoxetine is about twice what is currently 
being used in on-going clinical trials [3,4].
Exclusions
In this study, we examined infarct sizes in all animals that 
underwent stroke and also displayed at least a 20% contralateral 
deficit in the Montoya Staircase or Forelimb Asymmetry. In our 
endothelin-1 induced stroke method, we positioned a needle 
with endothelin-1 at a depth of 2 mm from the cortical surface 
before injecting 600 pmoles of endothelin-1 into the site. This 
movement of the needle through the cortex sometimes nicks a 
blood vessel and causes some bleeding, which the endothelin-1 
will generally stop for an interval. One of the animals in the control 
group had substantial bleeding due to this needle damage of 
blood vessels (Figure 3; Panel A: positive control for hemorrhagic 
infarcts), which produced secondary hemorrhagic damage in this 
animal and a huge infarct that spread far anterior and posterior 
compared to our normal infarcts (total infarct volume of 53.20 
mm3). Because this damage was due to a surgical artifact, and 
not due to the endothelin-1 induced ischemic damage, it was not 
included in this study. The only other reason that a rat brain was 
excluded from this analysis was if the brain was damaged either 
during dissection or during the cryostat sectioning, such that 
we could not mount the individual slices or could not accurately 
determine the entire infarct volume. 
Infarct volumes vary with timing of fluoxetine, 
statin administration
In Figure 1, infarct volumes were calculated on post-stroke day 
91, with animals either receiving fluoxetine and simvastatin (FS 
in figure, 5 mg/kg, and 1 mg/kg, respectively) or vehicle control, 
Histology
The animal was anesthetized with 100mg/kg, i.p. pentobarbital 
(Euthasol®), then euthanized by cardiac perfusion with phosphate-
buffered saline followed by 4% paraformaldehyde in phosphate 
buffered saline. The brain was dissected out, the left hemisphere 
marked, and the brain post-fixed 24 hours in 4% paraformaldehyde 
in phosphate buffered saline. The brain was then put into a 30% 
sucrose solution for three days, in preparation for cryosectioning. 
Fifty micron coronal slices were cut on a cryostat and collected 
into phosphate buffered saline. For infarct measurement, these 
sections were mounted onto gel-subbed slides, then stained with 
Nissl stain [6], dehydrated and coverslipped with DPX mountant 
(Sigma-Aldrich). 
Infarct measurement
 Brightfield images were taken of the sections using a 4X 
objective, then montaged using Adobe Photoshop 7.0 (Adobe 
Systems Inc, San Jose CA, USA) into a complete picture of any 
damaged regions of the brain. Area of the infarct was determined 
with ImageJ software from NIH. We determined infarct area 
(mm2) for every third or fourth slice, then multiplied by the slice 
thickness (mm) and either 3 or 4 respectively, to determine the 
complete infarct volume in mm3. Individuals determining the 
infarct volume were blinded to the animal group (control group 
or fluoxetine-simvastatin group). We lost four brains in the 
fluoxetine-simvastatin treated group for 6-12 hour administration 
and two of the fluoxetine-simvastatin treated group (20-26 hour 
administration) due to damage while cutting the brains on the 
microtome (shattering), which made the brain slices impossible 
to mount on slides or damage to brain while dissecting that made 
determination of complete infarct volume impossible. 
Statistics
An unpaired t-test with Welch’s correction for unequal variances 
was used for statistical comparison of the infarct volumes (Prism 
6.0, GraphPad Software Inc. San Diego, USA). Figure 1 shows 
means and standard error of the means, with individual infarct 
volumes given by closed symbols clustered around means. 
Sample sizes are given in the figure legends. The online relative 
risk calculator from the MedCalc site (www.medcalc.org/calc/
relative_risk.php) was used to determine the relative risk of the 
stroke rats developing secondary hemorrhagic stroke due to drug 
combination administration time and Fisher’s exact test (two-
tailed) was used to determine if there was a statistical difference 




Female Sprague-Dawley rats (10-12 months old, 300-400 grams) 
were initially trained to pick up sucrose pellets in the Montoya 
Staircase [5] and also tested for forelimb bias using the Forelimb 
Asymmetry Test [6]. We chose old rats as an animal model to 
better model the human stroke population, as neurogenesis is 
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beginning either 6-12 hours or 20-26 hours after stroke induction 
and continuing daily through post-stroke day 90. In Panel A, 
we see a strong trend toward a reduction in infarct size in the 
FS group (3.051±0.3447 mm3, mean±SEM; squares) compared 
to control (6.277±0.14 mm3, mean±SEM; circles) when the 
fluoxetine and simvastatin drug combination is administered 
beginning 20-26 hours after the stroke (P=0.0569; Welch’s 
correction on unpaired t-test with unequal variance), which was 
an unexpected result. We did not think drug administration this 
late after stroke induction would have any effect on the infarct 
volume. The reduction in infarct volume has also correlated with 
an increase in motor functional recovery, referenced in some of 
our previous work [6]. We next tested whether an earlier time 
point for drug delivery would result in further reduction of infarct 
volume and greater functional recovery, administering the drugs 
6-12 hours after stroke induction, a time period over which the 
majority of stroke patients have been shown to arrive at the 
hospital [1]. In Panel B, we see that drug delivery at an earlier time 
point actually resulted in larger infarct volumes (15.24±4.26 mm3; 
mean±SEM; squares) which were not statistically different from 
control infarct volumes (9.775±2.786 mm3; mean±SEM; circles) 
(P=0.1347; Welch’s correction for unpaired t-test with unequal 
variance). In panel C, we directly compared the infarct volumes 
in the two groups that received fluoxetine and simvastatin, just 
looking at the effect the difference in delivery time (noted on the 
X axis) had on the infarct volume. This data was simply taken from 
panels A and B, re-plotted on the same scale and then compared 
for statistical difference. Earlier delivery (6-12 hours after stroke) 
resulted in statistically larger infarcts (circles; mean of 15.24 
mm3) compared to later delivery times (20-26 hours after stroke; 
squares; 3.051 mm3 mean) (P=0.017; Welch’s correction of 
unpaired t-test with unequal variance). Since this was a surprising 
result, we examined the infarcts closely to determine why the 
infarct size was enlarged.
Histological evidence of secondary hemorrhagic 
transformation in rats receiving fluoxetine and 
statin at an early time point
In Figure 2, infarcts are shown (outlined with dashed lines) in 
representative coronal brain sections for each of the relevant 
groups. The endothelin-1 injection site was usually clearly seen 
at the dorsal portion of the cortex as it is generally a hole in 
the tissue at 91 days post-stroke, since it was the origin of the 
infarct. In control animals (Panels A and C), we have generally 
seen additional damage to the right side of this injection point, 
representing perhaps reperfusion damage when the endothelin-1 
was metabolized or eliminated, allowing blood flow to return 
after approximately 24 hours [16]. Areas with very small surface 
damage were not included in outlined infarcts just for clarity in 
this figure, but they were included in the infarct analysis above. In 
general, we did not see evidence of any secondary hemorrhagic 
stroke in control animals, whether or not the control vehicle was 
delivered at 6-12 hours after stroke (Panel A) or 20-26 hours after 
stroke (Panel C). 
Panel D shows the infarct size (largest in a series of brain sections) 
from an animal given fluoxetine and simvastatin 20-26 hours after 
 
Infarct volume varies with timing of fluoxetine and simvastatin delivery after ischemic stroke.  
Infarct volumes were assessed in rats at post-stroke day 91, and drug-treated rats received 5 mg/kg fluoxetine and 1 mg/
kg simvastatin daily in vehicle, beginning at the time indicated in the panel. FS in the figure refers to animals receiving 
fluoxetine and simvastatin. 
Panel A: Panel shows infarct volumes assessed in rats receiving either vehicle control (circles, N=8) and or drugs in vehicle 
(squares, N=6) beginning 20-26 hours after ischemic stroke induction and continuing daily until the end of study. Infarct 
volumes showed a strong trend of reduction, but just missed a significant difference (P=0.0563, Welch’s t-test) for the 
fluoxetine and simvastatin group. 
Panel B: Panel shows infarct volumes when either vehicle control (circles, N=8) or drugs in vehicle (squares, N=11) was 
delivered 6-12 hours after ischemic stroke induction and continued daily until the end of study. Infarct volumes showed no 
statistical difference (P=0.1347; Welch’s t-test). 
Panel C: Panel shows direct comparison of infarct volumes for the group receiving fluoxetine and simvastatin with different 
delivery times after stroke induction. The timing of delivery after stroke produced a significant difference in infarct volumes 
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stroke induction. You only see the original damage associated with 
the endothelin-1 injection at the core of the infarct, but the rest 
of the cortex appears to have normal Nissl staining. In contrast to 
control animals, there does not appear to be damage to the right 
of the original site, perhaps indicating that reperfusion damage 
was minimized. Alternatively, the fluoxetine and simvastatin are 
both known to increase growth factors in the brain, and we have 
shown in a previous study [6] that one of these growth factors, 
brain derived neurotrophic factor (BDNF), is elevated around 
the site of the original infarct; this may allow tissue around the 
original infarct to survive.
Out of 12 control animals with vehicle delivered at 6-12 hours, 
we saw two that had possible signs of secondary hemorrhagic 
infarcts (infarcts were located either far anterior or far posterior 
and dissociated away from the original infarct). One of these 
substantial bleeding occurred when lowering the needle into the 
cortex, so was an artifact of the surgical procedure. An example 
of this is shown in Figure 3, panel A, illustrating the extensive 
bleed from surgical artifact compared to a possible secondary 
hemorrhagic transformation. One control animal did show some 
posterior lateral damage, which may have been caused by a 
secondary hemorrhagic infarct, so we did include this animal when 
we compared relative risk of secondary hemorrhagic infarcts. In 
contrast, when we examined fluoxetine and simvastatin delivery 
6-12 hours after stroke (Panel B), we found more evidence of 
secondary hemorrhagic stroke, clearly dissociated from the 
original endothelin-1 injection site (e.g. ventral location, location 
in other hemisphere, far anterior or posterior to original injection 
site): Six of the original 11 animals in the early delivery FS 
group showed signs of secondary infarcts. The relative risk was 
calculated to be 4.36 (95% CI=0.64-29.5) for these small groups 
(6 positive outcomes and 5 negative outcomes) for the treated 
group to have a bad outcome compared to control (1 positive and 
7 negative). 
Discussion
A number of animal studies have looked at fluoxetine 
Representative images showing coronal brain sections with infarcts from groups shown in 
Figure 1.
Panel A:  Control vehicle 6-12 hours after stroke induction.  Coronal right hemisphere clearly 
shows injection site for endothelin-1 and then enlarged infarct continuing from this initial 
area of damage (outlined with dashed lines).
Panel B:  Fluoxetine and simvastatin 6-12 hours after stroke induction.  Coronal right 
hemisphere shows posterior portion of injection infarct (near top of cortex, enclosed by 
dashed lines) as well as a completely dissociated secondary hemorrhagic infarct (lower 
portion of right hemisphere, enclosed with dashed lines).  In a majority of images from this 
group, we found evidence of secondary hemorrhagic infarcts appearing in either the right or 
left hemisphere, which accounts for the larger infarct volumes associated with this group.  
Panel C:  Control vehicle 20-26 hours after stroke induction.  Infarct size was similar to that 
seen in Panel A; we just show the portion of the cortex with the infarct (outlined by dashed 
lines). 
Panel D:  Fluoxetine and simvastatin 20-26 hours after stroke induction.   This figure shows 
the largest damage in a coronal section from this group, with the infarct centered around the 
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administration in stroked animals or traumatic brain injury animals 
and many have failed to see any positive effect of the fluoxetine 
[17-19]. In several of these studies, neurogenesis is examined in 
the dentate gyrus, with only cursory examination of neurogenesis 
in lateral ventricles that are very posterior in the brain (to the side 
of the hippocampus). Also, the delivery method for fluoxetine is 
generally one which would induce stress in the animal (surgical 
implantation of an osmotic pump delivering fluoxetine, daily 
intraperitoneal injections of fluoxetine, oral gavage of fluoxetine, 
etc.). We have seen increases in neurogenesis in older (10-12 
month) rats in the subventricular zone (SVZ) of the anterior lateral 
ventricles in the presence of fluoxetine when it is given with 
voluntary oral administration, thus eliminating any stress with 
administration of the fluoxetine. We also see functional recovery, 
which correlates well with what is being seen in clinical trials of 
the drug in stroke patients[2,20] or traumatic brain injury patients 
[21]. Since stress has an inhibitory effect on neurogenesis and 
fluoxetine generally has a positive effect [22,23], we believe that 
care must be taken to eliminate stress when administering the 
fluoxetine to animal models of disease, which our drug delivery 
system accomplishes [8]. 
Both fluoxetine and simvastatin have been shown to increase 
vascular endothelial growth factor (VEGF) [14,24]. In the early 
delivery time, the formation of VEGF may cause bleeding because 
the normal proteins involved in structural support of angiogenesis 
are not yet available. In a study from Michael Chopp’s lab, 
early delivery (within 1 hour of induction) of rhVEGF to middle 
cerebral artery-occluded male Wistar rats showed signs of blood 
brain barrier leakage and hemorrhagic transformation, while 
later delivery (48 hours after stroke induction) did not [25]. This 
study may be the basis for beginning the fluoxetine post-stroke 
 
Hemorrhagic infarcts in control rats.  
Panel A: Positive control shows hemorrhagic infarct induced by excessive bleeding during the 
stroke induction surgery (needle hit a blood vessel).  Note that the secondary hemorrhagic 
infarct (red arrow) is very posterior to our normal injection site infarct (black arrow) and is 
completely dissociated from any cortical injury at the dorsal cortical surface.  
Panels B and C show anterior and posterior sections, respectively, from our one control 
rat that appeared to have a secondary hemorrhagic transformation.  Possible secondary 
hemorrhagic infarcts are marked with red arrows, while the endothelin-1 induced infarct is 
marked by a black arrow.
Figure 3
treatment no earlier than the second day post-stroke in ongoing 
Clinical Trials testing fluoxetine for motor recovery after stroke. 
We do not have direct evidence for increased VEGF immediately 
after drug administration yet, but from previous work on these 
drugs, the preceding was a potential explanation for why we saw 
hemorrhagic transformation at an earlier time point, but that 
hemorrhagic transformation disappeared at a later time point, 
although the drugs were exactly the same at both time points. 
However, given the results of this study and another study from 
this lab [6], it appears that giving fluoxetine 20-26 hours after 
stroke induction not only promotes motor functional recovery, 
but also reduces the infarct volume significantly compared to 
giving the fluoxetine and simvastatin within 6-12 hours of stroke 
induction. 
We are currently performing studies where the rats are on the 
statins prior to stroke induction, and fluoxetine is given at various 
times after stroke, so that the drug delivery will correlate better 
with what is seen during clinical trials with fluoxetine. We will 
directly compare fluoxetine delivery at 6-12 hours, 20-26 hours 
and 48-54 hours after stroke induction, and note impact on infarct 
volume at 7 days post-stroke and any trend towards hemorrhagic 
transformation. 
Conclusion
The combination of simvastatin and fluoxetine increased the 
relative risk (RR=4.36, 95% CI=0.64-29.5) of bleeding after 
ischemic stroke if it is given 6-12 hours after stroke induction in 
rats. However, delivery of simvastatin and fluoxetine 20-26 hours 
after ischemic stroke in rats significantly reduces infarct size 
compared to earlier delivery and shows a strong trend towards 
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